Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.56 USD +6.49% Intraday chart for Terns Pharmaceuticals, Inc. +0.15% +1.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating MT
North American Morning Briefing : Stocks Struggle After New Records DJ
JMP Securities Cuts Terns Pharmaceuticals Price Target to $15 From $17, Maintains Market Outperform Rating MT
BMO Capital Adjusts Price Target on Terns Pharmaceuticals to $19 From $18, Maintains Outperform Rating MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate MT
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Chief Executive Officer CI
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Member of Board of Directors CI
Jefferies Adjusts Terns Pharmaceuticals Price Target to $22 From $18, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $5.50 From $8, Maintains Neutral Rating MT
Mizuho Adjusts Price Target on Terns Pharmaceuticals to $10 From $17, Maintains Buy Rating MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity CI
Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) added to S&P Global BMI Index CI
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $8 From $11, Keeps Neutral Rating MT
Mizuho Ups Price Target on Terns Pharmaceuticals to $17 From $16, Keeps Buy Rating MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH CI
Terns Pharmaceuticals Chief Executive Senthil Sundaram Resigns Due to Health Reasons MT
Terns Pharmaceuticals, Inc. Announces Leadership Transition CI
Terns Pharmaceuticals Announces Leadership Transition CI
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Terns Pharmaceuticals Says New Preclinical Data of TERN-601 Shows Improved Glucose Tolerance in Mouse Model MT
Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session CI
Chart Terns Pharmaceuticals, Inc.
More charts
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.56 USD
Average target price
14.21 USD
Spread / Average Target
+116.68%
Consensus
  1. Stock
  2. Equities
  3. Stock Terns Pharmaceuticals, Inc. - Nasdaq
  4. News Terns Pharmaceuticals, Inc.
  5. Terns Pharmaceuticals' : Q2 Loss Narrows, Operating Expenses Increase; Shares Climb